Teva Pharmaceutical Industries Limited (TLV:TEVA)
Israel · Delayed Price · Currency is ILS · Price in ILA | Market Cap | 130.02B +76.7% |
| Revenue (ttm) | 51.58B +4.1% |
| Net Income | 2.10B |
| EPS | 1.79 |
| Shares Out | n/a |
| PE Ratio | 61.82 |
| Forward PE | 12.80 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,052,520 |
| Open | 11,200 |
| Previous Close | 11,130 |
| Day's Range | 11,030 - 11,260 |
| 52-Week Range | 6,082 - 11,530 |
| Beta | 0.88 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 4, 2026 |
About TLV:TEVA
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The com... [Read more]
News
Teva Announces Successful Pricing of $4.9 billion (Equivalent) Senior Notes
TEL AVIV, Israel, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today that it successfully priced its offering of approximately $4.9 b...
TEVA Initiates Coverage On Leerink Partners -- Rating Outperform
TEVA Initiates Coverage On Leerink Partners -- Rating Outperform
Leerink starts Teva with an Outperform with new strategy ‘clearly bearing fruit’
Leerink initiated coverage of Teva (TEVA) with an Outperform rating and $45 price target Teva’s “Pivot to Growth” strategy is “clearly bearing fruit,” evidenced by strong commercial execution and a…
Here are Wednesday's biggest analyst calls: Nvidia, Tesla, Dell, First Solar, Affirm, Teva, Robinhood & more
Here are the biggest calls on Wall Street on Wednesday.
Teva initiated with an Outperform at Leerink
Leerink initiated coverage of Teva (TEVA) with an Outperform rating and $45 price target
IEFA, SPOT, SE, TEVA: ETF Inflow Alert
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core MSCI EAFE ETF (Symbol: IEFA) where we have detected an ap...
Teva Launches Senior Notes Offering To Refinance Existing Debt
(RTTNews) - Teva Pharmaceutical Industries Limited (TEVA), a biopharmaceutical company, announced its intentions to issue senior notes through its special-purpose finance subsidiaries.
TEVA Looks 67.8% Overvalued on GF Value⢠as It Plans Debt Refinancing
TEVA Looks 67.8% Overvalued on GF Value⢠as It Plans Debt Refinancing
Teva Announces Launch of Offering of Senior Notes
TEL AVIV, Israel, Sept. 07, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today its intention to issue senior notes through its special purpose ...
After Hours Most Active for Sep 4, 2026 : NIO, INTC, TEVA, AMZN, F, NVDA, XOM, KO, CNH, ABUS, META, SMCI
The NASDAQ 100 After Hours Indicator is down -45.18 to 29,498.97. The total After hours volume is currently 112,199,562 shares traded.The following are the most active stocks for the after hours sessi...
TEVA Maintained by UBS -- Price Target Raised to $48.00
TEVA Maintained by UBS -- Price Target Raised to $48.00
S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline
S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline
Teva price target raised to $48 from $42 at UBS
UBS analyst Ashwani Verma raised the firm’s price target on Teva (TEVA) to $48 from $42 and keeps a Buy rating on the shares. The firm views the company’s Phase…
Biotech Gainers: BTAI Asset Deal, BIAF CyPath Growth, CYPH Zcash, GRI Pipeline Drive Gains
(RTTNews) - Today's top gainers in the biotech and healthcare space include BioXcel Therapeutics, following an asset sale agreement with Teva and Chapter 11 filing; bioAffinity Technologies, on strong...
A Look at Teva Pharmaceutical Industries Ltd (TEVA) After 3.6% Gain -- GF Value $20. ...
A Look at Teva Pharmaceutical Industries Ltd (TEVA) After 3.6% Gain -- GF Value $20.72 vs Price $37.49
Teva's TEV-408 Hits Key Phase IIa Endpoint in Celiac Disease Study
Teva Pharmaceutical Industries NYSE: TEVA reported positive topline results from a Phase IIa gluten-challenge study of TEV-408, its anti-IL-15 antibody candidate for celiac disease, with the company s...
Teva Reports Positive Phase 2a Results For TEV-408 In Celiac Disease
(RTTNews) - Teva Pharmaceutical Industries Ltd. (TEVA) announced positive topline results from its ongoing Phase 2a study of TEV-408, an investigational anti-IL-15 monoclonal antibody, in adults with ...
TEVA Looks 74.7% Overvalued on GF Value⢠as Phase 2a Trial Data Emerges
TEVA Looks 74.7% Overvalued on GF Value⢠as Phase 2a Trial Data Emerges
TEVA Looks 74.7% Overvalued on GF Value⢠as Positive Trial News Boosts Sentiment
TEVA Looks 74.7% Overvalued on GF Value⢠as Positive Trial News Boosts Sentiment
Teva's immune disorder drug meets main goal in mid-stage trial
Israeli drugmaker Teva Pharmaceutical Industries , said on Wednesday its experimental drug helped prevent gluten-related intestinal damage in adults with celiac disease, meeting the main goal of a m...
Teva Pharmaceutical Industries Transcript: Study result
TEV-408, an anti-IL-15 antibody, demonstrated statistically and clinically significant protection of gut architecture and symptom improvement in a phase II-A celiac disease study, with a strong safety profile and single-dose efficacy over three months. Plans are underway for rapid advancement to phase II/III and expansion into additional indications.
Teva Pharmaceutical Industries Slides: Study result
Teva Pharmaceutical Industries has posted slides in relation to its latest quarterly earnings report, which was published on September 2, 2026.
Teva Pharmaceutical Industries Press release: Study result
Teva Pharmaceutical Industries issued a press release on September 2, 2026, disclosing material business information to investors.
Teva reports TEV ‘408 study met primary endpoint
Teva (TEVA) announced topline results from an ongoing Phase 2a study of TEV ‘408, an investigational anti-interleukin-15 monoclonal antibody, in adults with celiac disease. The study met its primary e...
Teva Pharma Reports Positive Topline Results From Ongoing Phase 2a Study Of TEV 408
(RTTNews) - Teva Pharmaceutical Industries (TEVA) announced positive topline results from an ongoing Phase 2a study of TEV 408, an investigational anti-interleukin-15 monoclonal antibody, in adults wi...